Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kulke

Showing results (101-110 of 182) with videos related to

Pageof 19
Sort By:
Journal of Gastroenterology and Hepatology|June 6, 2013
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinomaDaniel J Renouf, Rihong Zhai, Bin Sun, et al.
Pancreas|August 29, 2018
Characterization of the Neuroendocrine Tumor Immune MicroenvironmentAnnacarolina da Silva, Michaela Bowden, Sui Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Activity of sunitinib in patients with advanced neuroendocrine tumorsMatthew H Kulke, Heinz-Josef Lenz, Neal J Meropol, et al.
The Journal of Clinical Investigation|May 21, 2026
Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogenyPratik Np Singh, Elsa Hadj Bachir, James R Howe, et al.
Endocrine-Related Cancer|July 12, 2014
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotideMatthew H Kulke, Thomas O'Dorisio, Alexandria Phan, et al.
Carcinogenesis|May 11, 2010
A Large-scale genetic association study of esophageal adenocarcinoma riskChen-Yu Liu, Michael C Wu, Feng Chen, et al.
Journal of Gastrointestinal Cancer|March 9, 2020
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid SyndromeJoseph S Dillon, Matthew H Kulke, Dieter Hörsch, et al.
Cancer Chemotherapy and Pharmacology|June 21, 2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu, Jeffrey W Clark, David P Ryan, et al.
The Journal of Molecular Diagnostics : JMD|August 11, 2007
DNA degradation test predicts success in whole-genome amplification from diverse clinical samplesFengfei Wang, Lilin Wang, Christine Briggs, et al.
Pancreas|July 29, 2010
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasMatthew H Kulke, Lowell B Anthony, David L Bushnell, et al.
Pageof 19

Showing results (101-110 of 182) with videos related to

Sort By:
Pageof 19
Journal of Gastroenterology and Hepatology|June 6, 2013
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinomaDaniel J Renouf, Rihong Zhai, Bin Sun, et al.
Pancreas|August 29, 2018
Characterization of the Neuroendocrine Tumor Immune MicroenvironmentAnnacarolina da Silva, Michaela Bowden, Sui Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Activity of sunitinib in patients with advanced neuroendocrine tumorsMatthew H Kulke, Heinz-Josef Lenz, Neal J Meropol, et al.
The Journal of Clinical Investigation|May 21, 2026
Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogenyPratik Np Singh, Elsa Hadj Bachir, James R Howe, et al.
Endocrine-Related Cancer|July 12, 2014
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotideMatthew H Kulke, Thomas O'Dorisio, Alexandria Phan, et al.
Carcinogenesis|May 11, 2010
A Large-scale genetic association study of esophageal adenocarcinoma riskChen-Yu Liu, Michael C Wu, Feng Chen, et al.
Journal of Gastrointestinal Cancer|March 9, 2020
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid SyndromeJoseph S Dillon, Matthew H Kulke, Dieter Hörsch, et al.
Cancer Chemotherapy and Pharmacology|June 21, 2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu, Jeffrey W Clark, David P Ryan, et al.
The Journal of Molecular Diagnostics : JMD|August 11, 2007
DNA degradation test predicts success in whole-genome amplification from diverse clinical samplesFengfei Wang, Lilin Wang, Christine Briggs, et al.
Pancreas|July 29, 2010
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasMatthew H Kulke, Lowell B Anthony, David L Bushnell, et al.
Pageof 19